Category Archives: Stem Cell Doctors


South Shields cancer survivor bursts into tears as she finally meets the woman who saved her life – Chronicle Live

A cancer survivor has finally met her anonymous saviour almost a decade after her transplant.

Becca Anderson, from South Shields, was diagnosed with leukaemia ten years ago.

As a student aged 18, Becca often felt ill but thought it merely was the result of stress and working too hard, but blood tests confirmed something far more serious.

The 28-year-old said: Id been poorly for a few months and I was actually on my way to a party when I got the phone call from my dad.

"Id had a blood test and the doctor rang the house phone trying to reach me but because of how serious it was, they told him to call me and get me to the hospital straight away."

At Sunderland Royal Hospital accompanied with her boyfriend and her mum, doctors informed Becca she had leukaemia.

"I just remember saying, 'Im going to die. Im going to die', she said.

"I calmed down but there were a lot of tears, it was dramatic."

Due to the high chance of relapse, Becca was told she would need a stem cell transplant if she were to be cured of her cancer.

Without a match within her family, the charity Anthony Nolan searched the stem cell register. Fortunately, a match was found soon after.

On November 2010, Becca went into hospital where she had her transplant and remained in isolation for two months.

Speaking of her journey to recovery, Becca said: "Its only really been the last two or three years that Ive fully got my confidence back. Everyones journey will be different, but recovery is hard."

Her donor was Susan Fullerton, from Glasgow, who joined the Anthony Nolan stem cell register on April 2010 after losing her mum to acute myeloid leukaemia in 2003.

Susan, 38, said: "I could remember how much blood transfusions gave my mum almost immediate colour and energy, so I decided to become a blood donor.

"At one of my donation sessions there were leaflets on the table about Anthony Nolan, so I decided to sign up."

Anthony Nolan gives people with blood cancer a second chance of life by finding them matching donors.

It also carries out ground-breaking research to save more lives and provide information to support patients after a stem cell transplant.

Lifesavers like Susan have a 1 in 800 chance of being called up to donate in the following five years. However, Susan was found to be a match just weeks after joining the register.

Both Beccas and Susans identity was kept secret from each other for two years as per the charitys procedure.

After the period passed, they were both allowed to meet each other. In September, nine years after surgery, both of them almost by chance decided to reach out to the charity within a few days of each other.

Becca, now a cabin crew member for Virgin Atlantic, was planning to do the Great North Run for Anthony Nolan and thought it would be the perfect timing for her to meet the stranger who saved her life.

Susan on the other hand wanted to share her story to encourage people to join the stem cell register due to her friends young child currently being treated for leukaemia.

When she decided to reach out she was surprised Becca wanted to do the same.

"It was no-brainer, I felt like I was missing part of my story, said Susan.

Becca said: "It was so overwhelming as it happened so quickly. Meeting my donor was a pipe dream and next thing I knew she was coming to Newcastle."

When they finally met at Central Station a day before the Great North Run, they hugged each other and burst into tears.

Speaking of their meeting, Becca said: "Meeting her was like meeting a friend. It was like a strange blind date that you just knew was going to work out."

Susan also felt a connection and said: "It never felt like I didnt know her. It just felt like I had known her my whole life, maybe it was because she had a piece of me inside her."

Becca and Susan plan to stay in touch and will meet each others families next month.

Looking back, Becca said: "Without Anthony Nolan and Susan, I genuinely wouldnt be here. I now see so many people not getting matches and I just think, 'wow, how lucky was I?'

"Looking back, I was so naive at the time. I never thought I wouldnt find a match."

Find out more about the work of Anthony Nolan at http://www.anthonynolan.org

See the rest here:
South Shields cancer survivor bursts into tears as she finally meets the woman who saved her life - Chronicle Live

VIDEO: Cancer survivor meets the donor who saved his life at a runDisney event – Inside the Magic

Get the tissues ready- for two runDisney participants this years Disney Wine & Dine Half Marathon culminated with an outpouring of gratitude and emotions.

Boyd Dunleavy is a Canadian runner who was diagnosed with acute myeloid leukemia, a rare blood cancer, in 2011. Dunleavys doctors estimated that he would have about a 10% chance of living more than just a few months if his medical team was unable to find a matching stem cell transplant donor outside of his family. Miraculously, after various treatments and a cancer relapse in 2012, Dunleavys doctors found a match- Nathan Barnes.

When Barnes was identified as a match, he was stationed in Japan as a gunners mate in the US Navy, but he was still able to donate the stem cells that would ultimately save Dunleavys life. Dunleavy was awestruck upon learning that a match had been found and that his donors name was Nathan: When we found out it was a gentleman named Nathan, it was incredible, he said, Our middle sons name is Nathan, and it means Gift of God.'

While recovering from the transplant procedure, Dunleavy began to use running as a recovery aid, which quickly turned into a passion. Since his transplant, hes become an active participant in runDisney events having completed two marathons, multiple virtual races, four half marathons, and a few 10K races.

Dunleavy ran in this years Disney Wine & Dine Half Marathon, and after seven years of being stationed overseas, Barnes was able to attend the race and finally meet Dunleavy and his family. Barnes met Dunleavy at the finish line of this years race to award him his medal.

My motto is never lose hope,' explains Dunleavy, Life is a special gift. We were told that with the stem cell transplant, my chances of living five years were only 30 percent. This is Year 7! Never lose hope.

Source: Disney

The rest is here:
VIDEO: Cancer survivor meets the donor who saved his life at a runDisney event - Inside the Magic

Global Regenerative Group Enters Into Distribution Partnership with Aurafix & Remodem – Benzinga

Global Regenerative Group, a proven company in the field of medicine and innovation, is pleased to announce partnerships with Remodem and Aurafix.

Boca Raton, FL, November 09, 2019 --(PR.com)-- Remodem is a company offering an innovative product with an interesting mechanism of action.

A new molecule, external inorganic gel liquid magnet, has been developed using a combination of silica, calcium chloride, and tetrahydropiperine, which have a very high water holding capacity. External inorganic gel liquid magnet is a new generation, patented molecular structure with a high hydrophilic feature that is not likely to be absorbed into the skin.

It is applied as a layer with a minimum thickness of 3mm to cover the entire edema area that occurs after tissue trauma. The area of application is then covered with sterile bandage for twelve hours.

This unique product, Remodem Superficial Swelling Reducing Gel, helps to reduce swelling and discoloration that occur due to sprain, muscle strain, trauma, sports injury, as well as aesthetic and plastic surgeries. As Remodem is used in many fields of medicine, this partnership will bring the Remodem product line to GRGs network of professionals around the world and allow the company to reach its full potential.

With its beginnings in a small workshop, Aurafix has continually improved itself by paying attention to the importance of quality, workmanship, and superior service as well as investing in human capital and technology. Aurafix has been an application center in the fields of orthesis, prosthesis and rehabilitation since 2002.

The Aurafix products are focused in three areas: Orthopedics, Liposuction, and Compression. All of the products manufactured are flawlessly delivered to users using a strict quality control process that ensures accordance with the relevant standards:

- Adhesive VELCRO surfaces provide comfort and ease of use.- Flexible neoprene material provides ease of movement and a warming, soothing effect along with high strength. Increased body temperature accelerates the healing process by increasing blood circulation.-A flexible cotton fabric with high air permeability. The flexible structure provides the required support and comfort by wrapping the body.

The company continues to grow and operate as a leading brand name in the domestic market. By partnering with Global Regenerative Group, Aurafix will become a worldwide recognized brand.

Aurafix offers 240 different Orthopedic products, 50 Liposuction, and 50 Compression products.

For full product list please see the catalogues:

- Aurafix Orthopedics- Aurafix Liposuction- Aurafix Compression

Of the agreement, the President of Global Regenerative Group, Randolph Beimel said, The Global Regenerative Group is a medical community comprised of doctors, scientists, hospital administrators, businessmen, and entrepreneurs in more than 35 countries; all focused on developing the newest and most innovative products to provide the best possible outcomes for the patient. The GRG relationships around the world give us the opportunity to identify the highest quality products in a particular country and distribute them globally. The international launch of the Aurafix and Remodem product lines will offer patients on four continents the same benefits that patients in Turkey have experienced for many years.

Global Regenerative Group is a fast-growing company, collaborating with specialists and clinics around the world, with the primary purpose of delivering innovative medical care to the patient. During the last decade the company has developed extensive experience in the most advanced medical device industries. Recently, the company's emphasis has been focused exclusively on Regenerative Medicine, such as stem cell technologies, products, and therapies.

Global Regenerative Trade, a subsidiary of Global Regenerative Group, is dedicated to bringing science in practice through product development. Our main mission is supporting and accelerating the healing process following medical treatment by enhancing the bodys own capabilities. Global Regenerative Trade serves as a hub, bringing together products used in various fields of medicine. Using cumulative knowledge and expertise in the field of Regenerative medicine, we develop products which enhance the quality of life of patients and are more user-friendly for doctors.

Contact Information:Global Regenerative GroupRandy Beimel954-778-2581Contact via Emailglobalregenerative.group

Read the full story here: https://www.pr.com/press-release/798942

Press Release Distributed by PR.com

Link:
Global Regenerative Group Enters Into Distribution Partnership with Aurafix & Remodem - Benzinga

Can mfines Hospital Network Bridge The Gaps In Indias Healthcare Delivery Systems – Inc42 Media

mfine enables patients to get doctor consultations virtually through its app interface

It claims to have touched 2,75,000 patients, handling an average of 1.5K consultations per day

The IBEF has estimated the Indian healthcare market to be valued at $372Bn by 2022

The healthcare industry in India is said to be one of the fastest growing sectors backed by Indias rising income, health awareness, and access to insurance, but also due to the increase in lifestyle and stress-related diseases. The IBEF has estimated the Indian healthcare market to be valued at $372Bn by 2022.

In India, the doctor to patient ratio in the allopathy sector stands at 1:1596 (far lower than the 1:1400 WHO standard) and the country is ranked 145 among 195 countries on the healthcare index.

Tapping the urgent need for improved healthcare data and quality access to doctors, telemedicine startups have sprouted in many cities in India. Telemedicine startups essentially help patients get doctor consultations virtually through apps or web-based videos, chats and voice guidance.

According to a Mckinsey report, India could save up to $10 Bn in 2025, by using telemedicine instead of in-person doctor consultations.

While, Practo has definitely become the most recognised player in the telemedicine space. Companies such as Lybrate, DocsApp, Medcords and mfine are also attempting to solve Indias healthcare problem in their own distinct ways.

One of the major challenges in telemedicine has been the process of onboarding doctors and building patients trust in digital consultations. mfine approaches this problem through hospital collaborations which help the company to ensure the quality of doctors, get access to a wide range of services and also drive patients trust because of the hospitals brand recognition, cofounder of mfine, Ashutosh Lawania told Inc42.

Bengaluru-based was founded in 2017 by former Myntra executives Lawania and Prasad Kompalli and later joined by Ajit Narayanan and Arjun Chaudhary. It counts SBI Holdings, SBI Ven Capital, Prime Venture Partners, BEENEXT, Stellaris Venture Partners, Alteria Capital and Mayur Abhaya CEO of stem cell banking company LifeCell, as its investors. It has raised a total of $22.9 Mn across three funding rounds.

mfine is focused on onboarding private hospitals within the range of 50 to 1000 beds.The company majorly wants to target 7000-8000 large hospitals which have pan-India presence, and offers all kinds of specialities and facilities.

mfine currently has over 200 hospitals and 750 plus doctors across six cities including Hyderabad, Delhi, Bengaluru, Pune, Mumbai and Kolkata. Some of the notable partners include Sunshine, Apollo Bangalore, Cloudnine, KIMS Hyderabad, Fortis Mumbai and Sarvodaya among others. In the past 12 months, mfine claims to have touched 2,75,000 patients, handling an average of 1.5K consultations per day.

The company operates on a B2C model, on every new lead generated whether online consultation or physical visit at the hospital, the company takes certain commission and a part of it is shared with the partner hospital. This means hospitals are incentivised to tie-up since it increases their patient inflow and also lets more people access its services, who would have otherwise not approached the hospital.

Though the company did not share the commission rate it charges partner hospitals, each consultation is said to be priced between INR 500 800 for patients, varying with cities and the type of hospitals. It also offers health-check packages and a monthly subscription called mfine ONE, which includes a free baseline health checkup and unlimited access to doctors.

Talking of the user demographic, Lawania said that 60%-65% users are from Tier 1 cities, while Tier 2 and Tier 3 make up for 30%-35% share of the companys user base. The company plans to expand into 40 cities in India over the next couple of years through hospital partnerships to bring more top doctors onto mfine. Also, mfine agreed to the possibility of entering the health insurance space by partnering with existing players in the insurance industry.

The Indian government has also been contributing towards improving access to healthcare growth with policies such as Pradhan Mantri Jan Arogya Yojana (PMJAY), which promised to provide health insurance worth INR 500K (roughly $7k) to over 100 Mn families annually.

Even after multiple attempts by the Indian government, the biggest gap in the Indian healthcare system is providing access to healthcare at the bottom of the pyramid. Most of the rural population in India find it hard to avail quality healthcare both because of geography and high healthcare costs.

While, mfines model of collaborating with hospitals does allow it to easily onboard doctors and patients, thanks to the high-ticket consultation fees at large hospitals, access to healthcare services is again limited to high income families only, who already have access to quality healthcare.

Contrary to mfines network of hospitals model is Medcords, which runs a network of local pharmacies which has helped the company to gain significant user base in the rural areas. Medcords told Inc42 in an earlier conversation that the startup chose not to partner with hospitals because that will potentially create a barrier for low income families. On the other hand, Practo tied up directly with medical practitioners and doctors to improve access.

Responding to this, Ashutosh said that the company is currently focussed on building a cloud network of quality private hospitals. However, it is also considering partnering with public hospitals at a later point in time, which would greatly help increase the affordability.

Ultimately that should be the end goal for most telemedicine startups that are hoping to improve access to healthcare. While in the urban context, partnering with private hospitals makes admissions and consultations easier for patients, its the rural population that is most in need of improved access to quality doctors and healthcare.

See the rest here:
Can mfines Hospital Network Bridge The Gaps In Indias Healthcare Delivery Systems - Inc42 Media

Making a Better Baby – Vision Insights and New Horizons

We always want to make things better. Recreating the world according to both our needs and our abilitiesstraightening the crooked branch, as it wereis our long-standing pattern, with a particular focus on life around us. Although weve known about the twisting branches of the DNA molecule at the heart of our tinkering for only 65 years or so, weve been breeding and crossbreeding for millennia in hopes of producing the biggest, the smallest, the tastiest or the hardiest.

Moving on to gene-splicing and now gene editing, we continue to reconfigure species to fit our desires. Whether dog, fish, tomato or soybean, many species and crops being marketed today are the product of our own design. In the future we may even endow our creations with genes and chromosomes created from scratch. Artificial intelligence can already dissect protein structure and function; from this may come the ability to design new proteins and then, taking one more hereditary step back, build their corresponding DNA sequences. Inserting these into embryonic cells would give the adult organisms new capacities and metabolic pathways never seen before.

How might we engineer our future children and, by extension, the human family as technology opens new doors to prune and straighten the next generation? Just imagine the possibilitiesand the pitfalls.

What would you be brave enough to do? Or not do?

Trees grow in all kinds of ways. Theyre not all perfectly straight. Not every limb is perfect.

Consider organ transplants. Soon someone will receive the first heart or kidney grown in a pig. In this case the pig genome will have been altered to silence or remove proteins that trigger the patients immune response, thus avoiding patient rejection.

But why not just make the pig more human? Human-animal hybrids are controversial but not out of the question. How about adding human stem cells to chimpanzee embryos? Michael Crichtons 2006 novel NeXT plays out just this kind of chimeric humanization-of-animals storyline.

Weve not yet grown a transgenic organism to term, but someday we likely will. The scientific impetus to use such an integrated platform to understand more about brain development, for example, may eventually overcome the ethical questions that so often arise in the surrounding moral ether.

What will actually happen next in human applications? In the 20th century, the focus was on controlling the outbreak and spread of infectious disease. The discovery of antibiotics and the development of vaccines, as well as access to clean water, were pivot points in human health.

As we moved into the 21st century, attention shifted to the human cell. The infectious-disease assault will continue, but what if we could edit disease out of the human genome altogether? This is such a fantastical thing to think about, Jennifer Doudna told Vision in 2016. You suddenly realize, Wow, we have a tool that in principle allows us to change human evolution. We can wipe out a mutation from the whole populationjust get rid of it.

Doudna, University of CaliforniaBerkeley professor of chemistry and molecular and cell biology, worked with Emmanuelle Charpentier (now at the Max Planck Unit for the Science of Pathogens in Berlin) to unlock the gene-editing potential of CRISPR-Cas9. When we came across this protein in the bacterial immune system, we werent looking for that, of course, Doudna explained; but once we understood how it worked we realized this would be an incredible tool for genome editing. Because we can program it with this little piece of RNA, we can make a break wherever we want to.

This means that scientists now have the molecular scissors and aiming system to make a specific edit among the 3 billion base pairs in our genome. Finding one particular letter in our DNA (the one incorrect letter on chromosome 11 that causes sickle-cell disease, for instance) is like finding one particular a in a stack of 900 Bibles; yet in any genomeanimal or plantCRISPR can find that letter and change it.

This has revolutionized biology, says Doudna.

Now we have a tool that allows rewriting of the genetic code, changing the DNA in cells. Thats a profound thing. It allows scientists to do things that in the past would have been really hard or impossible.

Gene editing is not limited to the scientific community. The low cost of CRISPR and the relative ease of self-training has opened its use to almost anyone. The 2019 Netflix documentary series Unnatural Selection reveals just how fast the democratization of molecular science is moving. We have no choice but to continue exploring the tree of knowledge, says one geneticist, but we always run the risk of discovering something that we cannot handle.

DNA code is not like computer software. A person is more than code, children more than the genes inherited from their parents. Still, genes are critically important because the code they carry determines physiological parameters that affect our health and who we are. They do limit us in one way or another. A tall person is not going to be a champion jockey; a claustrophobe wont be a good astronaut. We want to avoid disease, yet often the crooked branch is what gives us identity, individuality, even extraordinary gifts. The concern now is that definitions of disease and crooked might become quite malleable.

While it seems more practical and effective to invest in improving the social, cultural and mental environment that influences our well-being, weve emphasized the path to greater genetic influence. A decade before the advent of CRISPR, Gregory Stock recognized this fixation on the human genome: The possibility of altering the genes of our prospective children is not some isolated spinoff of molecular biology but an integral part of the advancing technologies that culminate a century of progress in the biological sciences (Redesigning Humans: Our Inevitable Genetic Future).

Thanks to gene-editing tools such as CRISPR, as well as an emerging kit of DNA-cutting proteins that are even more precise, the next generation of control has actually arrived. Its no longer a question of if or how; now the questions are Should we? and When? Will we be able to collectively determine when its safe to proceed? And who will determine which traits to change? Scientific groups have proposed moratoria on experimentation while they struggle for answers. In the meantime, gene editing is going on off-campus, unsupervised, in garages and kitchens.

In terms of therapeutic editing of patients cells (for example, immune cells removed from an adult and then returned to fight cancer) the cautionary lights have turned green, and many clinical trials are underway. But when to proceed with germ-line editing is trickier. Central to germ-line editing is the embryo; and in this case, creating the embryo is the job of in vitro fertilization (IVF).

Robert Edwards, the fertility pioneer who, with Patrick Steptoe, developed the first techniques of IVF, substantiated Stocks view of the progression. Writing in 2004 concerning the potential therapeutic power of embryonic stem cells, Edwards noted that development in several fields of biomedicine hinged on past success with human IVF. Producing stem cells through the creation of embryos, he said, had been among the primary intentions of introducing human IVF (another, of course, was to help infertile couples have babies).

Having access soon after egg and sperm unite, when there are very few cells to scissor, makes it possible to change the trajectory of both an individual life and a family line. Because every cell of the body carries the same DNA information as the first, a change in those first embryonic cells becomes a change everywhere. Its also possible to go back one more step: egg or sperm cells can be edited prior to fertilization.

Individuals created with any such alterations will pass them on to their children; by definition, these genetic modifications will become part of the germ line.

He Jiankui, formerly a biophysicist at Southern University of Science and Technology in Shenzhen, China, calls the embryo-editing procedure gene surgery. Gene surgery is another IVF advancement, He says. For a few children, early gene surgery may be the only viable way to heal an inheritable disease and prevent a lifetime of suffering.

In 2015 the first report of human-embryo gene modification was published. Using nonviable IVF embryos from fertility clinics, other Chinese scientists had tested the accuracy of CRISPR edits in humans. This advance came surprisingly soon on the heels of Doudna and Charpentiers discovery in 2012. According to Edward Lanphier, then president of Sangamo BioSciences, the ubiquitous access to and simplicity of creating CRISPRs creates opportunities for scientists in any part of the world to do any kind of experiments they want.

This early attempt at human germ-line modification prompted the first International Summit on Human Genome Editing (Washington DC, 2016). Following the summit, Doudna shared her concerns with Vision: I would like to see the community of peopleall of us who are now living in a world where we have this technology availablecoming together to understand it well enough that we can think as a society about how to employ it in ways that will be beneficial to people and will cause, hopefully, no harm. We need to maximize the good while minimizing the risks and the dangers.

At the time, Doudna was optimistic and generally confident that everyone could work together to move forward.

We want to proceed in a way that is respectful of human life and that is cautious, but also appreciates that there are patients desperately waiting for treatments. We need to be balancing the benefits and the risks.

By what rules or principles should this science advance? At the Second International Summit on Human Genome Editing (Hong Kong, 2018), He Jiankuialso known as JKplanned to present a series of principles that he and his collaborators believed would provide a solid humanitarian and ethical basis for moving forward with germ-line editing.

In the paper, Draft Ethical Principles for Therapeutic Assisted Reproductive Technologies, He and his colleagues proposed that a core set of fundamental human values be set by the medical and patient communities to advance a dialogue about the ethical use of ART [Assisted Reproductive Technology, including IVF] to help fertility-challenged couples conceive healthy children. Parameters for early-in-life genetic surgery would be brief and simple so as to be accessible to the public: Lawmakers in countries wishing to permit clinical trials and eventual regulatory submissions could build on these values to write cohesive rules that can still account for their countrys distinctive mix of religious beliefs, culture, and public-health challenges.

Initially the paper, published in The CRISPR Journal, seemed reasonable enough: Gene surgeries, including CRISPR gene editing and mitochondrial donation techniques, promise new therapeutic strategies during in vitro fertilization (IVF) to cure or prevent these diseases before a child can suffer. The authors went on to ask, What should be our proposed ethics and actual red lines?

Stanford neuroscientist William B. Hurlbut talks about his dealings with the Chinese researcher who created the worlds first gene-edited babies, and about the implications of that experiment.

They asserted, We have thought deeply about ethical foundations for regulation in discussions between researchers, patients and advocates, and ethicists both in China and abroad. One of those ethicists was William Hurlbut, who described his impressions of He in an interview with Vision: JK is a very nice person to talk with and is sincere in wanting to do good. ... He kept saying to me, We have to get this moving along, because the science is safe. He was convinced the science was safe.

JKs paper suggested five principles for determining whether germ-line editing should be approved in any given situation:

Its hard to disagree with any of these ideas.

We hold additional but less universal beliefs that further restrict the use of gene surgery, the authors noted, including the need to prioritize local population health needs and focus only on treating disease via prevalent, natural genetic variants.

As already noted, He Jiankui planned to present this material during the Hong Kong conference. In an e-mail to Vision, the moderator of the session, Robin Lovell-Badge (Francis Crick Institute, London), confirmed the timeline: Yes, JKs draft presentation did include a few slides on his view of the ethics of human germline genome editing. This was, according to Kevin Davies, the editor of The CRISPR Journal, always slated to be published around the time of the Summit meeting.

Just as one of the major problems with CRISPR editing is the danger of off-target misedits of the genome, Hes plan unraveled when it became known that he had already used CRISPR nine months earlier to edit and implant embryos. News of the birth of twins, dubbed Lulu and Nana, became public on the eve of the conference.

Lovell-Badge continued, I am fairly convinced that JK did not want the story of the babies to break until [a second] paper describing them was being published in a top journaland he appeared genuine when he apologized that the story broke early. Lovell-Badge has written an extensive account of behind-the-scenes meetings that took place at the time.

Was He Jiankui angling to create a kind of consensus supporting his ethics statements before his actions came to light? Had the scientific community supported his Draft Principles, it could arguably have helped both He and others justify what had been done. The principles, had they been sincere, might have paved the way for acceptance of germ-line editing.

According to Jon Cohen of Science, JK was also laying the groundwork for a kind of germ-line tourism business. Who knows how quickly we might have traveled that path had his timeline not tipped over? In failing to adhere to the cautionary principles that had existed by general agreement since 2016, he derailed any insight his Draft Principles might have provided; they have been dismissed as merely a bid to justify his own actions.

Citing Hes obvious conflict of interest, The CRISPR Journal retracted the paper. Its chief editor told Genetic Engineering and Biotechnology News: The authors intentionally hid from us the fact that they were conducting clinical research on germline editing, and that babies had been born. ... It is a mesmerizing gaze into the psyche of the authors before the news came out and how misguided they were.

He Jiankui has been martyred as a rogue scientist, but his venture into the gene pool has made the waters even more enticing. If any Rubicon to germ-line editing existed, it has now been crossed.

We have spent billions to unravel our biology, not out of idle curiosity, but in the hope of bettering our lives. We are not about to turn away from this.

Its clearly turned up the heat, Eric Juengst, director of the Center for Bioethics at the University of North Carolina, told Wired. Hes leapfrogged the safety research that everyone was calling for. The pressure is increased to actually get that research done.

According to Juengst, the article notes, a world with enhanced humans via gene-editing is an inevitability. People will have to learn to live in a world in which there are gene-edited fellow people among us, he said. And thats another focus that governments could take, to worry less about policing the science, and worry more about preparing society to live with this new kind of genetic diversity.

New regulations may create hard lines against germ-line modification, but if Lulu and Nana are normal and healthy (which has not yet been independently confirmed), desperate and/or curious parents will find an avenue to give it a try. In his book Designing Babies: How Technology Is Changing the Ways We Create Children, Robert Klitzman of the Columbia University Medical Center notes how difficult it will be to close the now-open door to germ-line editing.

Pointing to weak regulations and the free-market approach to ART that exists in many countries, including the United States, Klitzman has little confidence that attempts to regulate future implantation of edited embryos will be effective. Even the United Nations, with representatives from every country, has restricted powers, he notes. At some point, the transfer of gene-edited embryos into human wombs will probably be approved for use on an experimental or wider clinical basisonce its risks are better characterized, even though dangers will probably persist.

Klitzman continues, Many doctors and would-be parents prioritize patient autonomy over the rights of the future child, and minimize potential longer-term medical, psychological and social risks of ARTs. Given, in addition, the lucrative and competitive, profit-driven ART industry and its overall resistance to strong guidelines, numerous doctors might thus end up performing these procedures, with little regulatory or administrative hindrance (Klitzmans emphasis).

Assisted reproduction can do more than help infertile couples have a baby. It can help couples have the baby they want. So while we strive for health, there remains the question of whether we will objectify our children. Will we reduce them to products, fine-tuned, straightened and genetically honed to the parents recipe? In a consumer-conscious and market-driven world, a few may soon have both the economic and medical resources to purchase germ-line enhancements. One IVF parent explained his thinking to Klitzman: If youre paying to get a child, and this technology is there, why not use it? You go car shopping. You dont just want something that has four wheels. You might want a Mercedes. Thats why theres so many different kinds of cars. I dont see anything wrong with it.

Will we be brave enough to deny ourselves that future?

Eat of the forbidden fruit, God warns, and you shall surely die. Eat, promises the serpent, and you shall be like God. That temptationto be like Godis at the root of the ethical dilemmas posed by molecular biology.

In a video that was meant to coincide with the preplanned public announcement of Lulu and Nanas birth, He Jiankui made a poignant request. While there is collective skepticism about his motivations, his plea rings trueto remember that these babies are simply children for whom their parents believed they were doing the right thing. Did the parents understand the full implications of what he was asking them to undertake? Probably not, but desperate parents dont always see beyond their hope for a well child; theyre apt to grasp at any offer of help.

We hope that you have mercy for them, He said. Their parents dont want a designer babyjust a child who wont suffer from a disease which medicine can now prevent. Gene surgery is and should remain a technology for healing. [Enhancement] is not what a loving parent does. That should be banned. He concluded, I believe families need this technology and I am willing to take the criticism for them.

Was this bravery or bravado? A self-serving sales pitch or an earnest plea? In time well know whether Hes work was pioneeringor disastrous. In the meantime the research and the debates will continue.

The dark side of human nature is always with us. In the face of new trends in the world around, we need to think about how we, as individuals, will proceed.

At this stage, Doudna says, I support the plans of WHO and the National Academies to recommend strict regulation that precludes use [of germ-line editing] until scientific and technical questions are addressed and until ethical and societal matters are resolved. I prefer this to a moratorium which, to me, is of indefinite length and provides no pathway toward possible responsible use. Open discussion and transparency around this important topic should be encouraged, not suppressed.

Can the conflicts of interest that obscure clearheaded discussion be overcome? Who will lead that discussion? Self-interest is a powerful motivator. Researchers would need to hold themselves back, especially from exploring genetic enhancement. To expect such a thing, however, is to believe that all of us will be willing to step back from the threshold. It seems more likely that some will want to use these new tools to try to straighten things that need not be made straight.

If there were a fifth horseman of the Apocalypse, perhaps he would be genetically modified and his horse spurred forward by self-deception. Is it bravery to forge ahead into a new world of human genetic modification that will lead, almost inevitably, to enhancement, or is it wiser to step back, to resist that temptationto pull back on the reins and strive instead to be content with our variety, our limitations and our crooked branches? That is our collective challenge in this brave new world of making babies.

Follow this link:
Making a Better Baby - Vision Insights and New Horizons

Arizona the "wild west" of stem cell therapy; experts say promising therapy ripe for exploitation – ABC15 Arizona

Arizona has been called "the wild, wild west" of regenerative medicine.

The Valley is one of the most popular places in the country for stem cell clinics. The new and controversial therapy is being marketed and practiced all over Phoenix and Scottsdale.

The less invasive procedure promises to heal pain, nearly anywhere in their body. It is advertised as effective, safe, and ethical, but outside experts and industry insiders say consumers need to do their research to avoid being exploited, and potentially spending thousands in cash on a worthless injection.

"IT HAS GREAT POTENTIAL"

The world of regenerative medicine is still being explored and developed.

"It actually gives you really good results," explained Dr. Matthew Hernandez, a naturopathic physician with Ethos.

"There's a lot of hope and promise, generally around the prospects for stem cells," said ASU Professor Emma Frow.

"Were still in the developmental stage. Stem cell therapy has been around for less than ten years. Thats new in medicine," said Dr. Steven Sorr, a naturopathic physician who runs Source of Health in Scottsdale.

"It encourages your own body to heal itself," said Janet McConnell, a 63-year-old bodybuilder who "had cartilage damage several years ago."

Instead of a surgery that would have derailed her competition training for months, she opted for injections.

"Three years ago, instead of the surgery, I had a PRP treatment," said McConnell. "It was very effective."

Years later, she returned to Dr. Hernandez for another round.

For most, Stem Cell and Platelet Rich Plasma (PRP) therapy is a mystery. "It's kind of controversial and experimental," said Matthew Riddle, Director of Sales for Celling Biosciences.

The treatments concentrate platelets or stem cells, usually from the patient's own blood. Experts say it is important to always ask the doctor or provider where the "growth factors" are coming from, because in order to ensure they are alive they should be coming from the patient's own blood, fat, or bone marrow. Otherwise, patients can receive "dead" stem cells, which are not nearly as effective.

"We are very adamant to use the patient's own cells," said Riddle, who uses a centrifuge to separate out the blood, saline and growth factors that will be re-injected. "When we inject that into an area, we are telling your body to go heal that spot," said Dr. Hernandez.

"Stem cell treatment is really about trying to take the stem cells out of your body and...inject them back into another part of your body, in order to try and heal whatever part of the body is suffering," said Professor Frow.

"IT'S THE NEW WAVE"

According to researchers, Scottsdale and Phoenix are two of the seven "hot spot" cities in the country.

Arizona State University professors Emma Frow and Dave Brafman spent years studying the industry , and mapping out dozens of clinics in the Valley. They believe there are many more, as some intentionally practice under the radar. "I don't believe right now that there is enough evidence to suggest that they work," said Professor Frow.

"They are unregulated, unproven and for-profit," added Professor Brafman.

The profits are plentiful. "There's cash involved, so this isn't covered by insurance," said Dr. Hernandez.

"PREYING ON PEOPLE'S PAIN"

The thousands in cash is one of many reasons the burgeoning industry is ripe for exploitation.

"The other piece too, it is it is new and upcoming," said Dr. Hernandez.

Many potential patients do not know the first thing about the procedure they are being sold, and doctors say many fall for sales tactics that are practiced at traveling seminars.

"They are preying on people's pain," said Dr. Sorr. "I think its really unethical and it upsets me."

Dr. Sorr believes the seminars are "a scam" that specifically targets an elderly clientele.

"They wine you and dine you. They go through a little dinner presentation and it is not the doctor, it's a marketing agency," he said.

The doctor told ABC15 he has had clients who have been duped, even after he told them they were not ideal candidates for stem cell or PRP therapy.

"It really broke my heart that he spent thousands upon thousands of dollars for something that was worthless.

"I don't agree with how they are done," said Dr. Hernandez. "They inject people and they get money. That's not practicing medicine, that is selling."

Both naturopathic physicians told ABC15 that some patients do not need the treatment, or will get subpar results from the injections. They say it is well known in the industry that some practices will continue to sell in order to reap the thousands in cash.

"ALL OF IT FALLS ON THE PATIENT"

Right now, there is little regulation or oversight of the industry in Arizona.

"Really all of it the falls on the patient, with very little recourse if things go wrong," said Dr. Emma Frow.

During the course of our investigation, ABC15 discovered the Arizona Medical Board and County Health Department do not take complaints or oversee the people performing injections. The federal government has also been slow to implement widespread regulation.

"The FDA has their hands tied," said Dr. Sorr. "There are too many people out there that are doing this that havent had the proper training, they dont have the right experience, the right tools and all that."

There are some larger regulations in Arizona, governing who can handle a needle and perform injections.

Unlike other industries though, including massage therapy, there is no board that checks on licensing or investigates complaints involving botched procedures or alleged fraud.

"The state medical boards, need to become a little bit more involved in sort of identifying, or responding to claims," said Professor Brafman.

"I don't think it would hurt to have it, for sure. At the end of the day it's about protecting the public," said Dr. Hernandez.

For thousands of Arizonans, like Janet McConnell, regenerative medicine has helped heal chronic pain. Before spending thousands thousands though, do your research. "Always get a second opinion," said Dr. Sorr.

"I think this is really a case of buyer beware, or consumer beware," said Professor Frow.

If you are planning on undergoing a stem cell or PRP treatment, click here for questions experts say you should always ask ahead of time.

See the original post:
Arizona the "wild west" of stem cell therapy; experts say promising therapy ripe for exploitation - ABC15 Arizona

Edmond 2-year-old fights big battle inside his tiny body – KFOR Oklahoma City

Please enable Javascript to watch this video

EDMOND, Okla. (KFOR) - Two-year-old Benjamin Brister winds up and kicks a football straight into his dad's chest, who doubles over laughing.

Benjamin is learning the simplest rules of football in his Edmond backyard with his dad and brother.

He likes football but loves playing "shark-tag" even more.

He hold his hand over his head like a shark fin, as he chases his family.

Benjamin is adorable, but he is also resilient beyond his years.

"He's always been a blessing to our family as far as calmness and tranquility," says his dad, Steven Brister. Last February, doctors at Jimmy Everest Cancer Center found a tumor in Benjamin's kidney.

The Bristers suddenly had to add the term "Wilm's tumor" to their vocabulary.

Megan Brister says, "They took out his left kidney. It just takes the wind out of you to hear your kid has cancer, no matter what type it is."

Benjamin underwent surgery to remove his cancerous kidney, which was followed by chemotherapy.

They thought they were heading into the "all-clear" five months later when a routine abdominal scan sent them reeling again.

"His scans came back not good. It had spread to his liver and his lungs, there were just lots of multiple size tumors all over."

"Less than ten percent of Wilm's tumors will relapse," says Dr. Chinni Pokala at Jimmy Everest Cancer Center.

He is now guiding the Bristers through a treatment that is more aggressive and complicated.

"Our hopes are between high dose chemo, stem cell transplant and then radiation to his lungs and liver, we're still optimistic he'll be cured," says Dr. Pokala.

Megan Brister credits the staff at Jimmy Everest Cancer Center for helping them cope with this difficult detour in treatment.

"They don't make it scary. It's all upbeat and happy and let's just get the job done."

The Bristers say Benjamin is his own tiny health advocate.

"He can give himself his own medicine, a syringe, he wants to do it himself. He flushes his port. He gets daily shots in his leg that he barely cries about now. he picks the legs and lays down for it."

The Bristers know they are in uncharted waters, but their path forward is filled with love and hope.

"We just want him to grow big and strong," says Megan.

If you'd like to help children like Benjamin fight cancer, consider donating to JECFriends.org

Go here to read the rest:
Edmond 2-year-old fights big battle inside his tiny body - KFOR Oklahoma City

Stem cell therapy giving disabled, elderly pets a second chance at life – CW39

Please enable Javascript to watch this video

A breakthrough medical procedure using stem cell therapy is transforming the lives of disabled pets, and their owners are documenting these transformations in astounding before and after videos some featuring dogs barely able to walk that are suddenly able to run.

Dr. Carmen Petti of the Avon Lake Animal Clinic said while stem cells are proven to help things like arthritis and skin allergies, it is still in the early stages for many diseases and ailments. It's also expensive, costing anywhere between $1,000 to $2,500.

The procedure requires sedation and a minimally invasive surgery where doctors remove two to three tablespoons of fat loaded with stem cells. In one study, 99% of patients saw improvements that lasted up to two years.

Doctors and patients say they are amazed at the improvement they've seen in their patients and pets. They also say that as the procedure becomes more common, it could also become cheaper and more affordable.

Follow this link:
Stem cell therapy giving disabled, elderly pets a second chance at life - CW39

Growing Human Organs In A Lab: As Scientists Develop Pathbreaking Three-Organ System, Heres All You Need To Know – Swarajya

In September end, a good news greeted the biomedical world when a team led by Takanori Takebe at Cincinnati Children's Hospital Medical Center succeeded at growing a connected set of three organs: the liver, pancreas and biliary ducts, in the lab, from human stem cells. The findings were published in journal Nature.

While human organoids already provide a sophisticated tool for research, the connected set of three organs, for the first time, allow scientists to study how human tissues work in concert. This was dubbed as a significant step forward.

In October, another news came. At the annual meeting of the Society for Neuroscience, researchers said that brain cell clusters prepared in the lab- a type of organoid- show abnormal behaviour as compared to the normal brain cells.

They said that the cells in these clumps had ambiguous identities and made more stress molecules than cells taken directly from human brains. However, these abnormalities were found to be alleviated a little bit when the implanted into a more hospitable environment - a mouses brain.

What are organoids?

With the available technology, scientists can grow a group of cells in laboratories into three-dimensional, miniature structures that mimic the cell arrangement of a fully-grown organ.

This is done using stem cells.

Stem cells are special human cells that have the ability to develop into many different cell types, from muscle cells to brain cells.

The embryonic stem cells that are derived from unused embryos (These are created from an in vitro fertilization procedure and used for scientific research) are pluripotent, meaning, they can turn into any type of cell.

On the other hand are adult stem cells. They are derived from fully developed tissues, like the brain, skin, and bone marrow. These cells often have capability of turning into only certain types of cells. For example, a stem cell derived from the liver will only generate more liver cells.

However, the adult stem cells can be manipualted in the laboratory to act like embryonic stem cells. These are called induced pluripotent stem cells. (The technique was developed in 2006). However, scientists are yet to find adult pluripotent stem cells that can develop every kind of cell and tissue.

When scientists create right environment in the laboratory for them, these stem cells follow their own genetic instructions to develop into tiny structures that resemble miniature organs composed of many cell types.

Using these, researchers have been able to produce organoids that resemble the brain, kidney, lung, intestine, stomach, and liver etc.

For example, in the three-organ research mentioned above, Dr Takebe started with stem cells from human skin cells and then guiding and prodding those stem cells to form two very early-stage "spheroids" of cells loosely termed the foregut and the midgut (In human embryos, these form late in the first month of gestation. Over time, they merge and morph into the organs that constitute the digestive tract).

The spheroids were first placed next to each other in a lab dish suspended in a gel used to support organoid growth, then placed on top of a thin membrane that covered a carefully mixed batch of growth medium.

From this point on, the cells knew what to do, and 70 days later, the mini organoids began processing bile acids as if they were digesting and filtering food.

Why are organoids important?

The technique to develop organoids was named by The Scientist as one of the biggest scientific advancements of 2013.

Organoids are an excellent tools to study biological processes like uptake of nutrients, drug transport, secretion of hormones and enzymes etc. This way, diseases related to malabsorption of nutrients, and metabolism-related diseases like obesity, diabetes, insulin resistance can be studied at the cellular-level.

Recently, scientists at the at Memorial Sloan Kettering created a tumor organoid to develop a more accurate rectal cancer model.

In the case of the human brain, organoids opens a window to understand some of the most complicated and hidden aspects of our own biology. They can be used to study neuropsychiatric or neurodevelopmental diseases like schizophrenia or autism spectrum disorder, which are uniquely human diseases that affect the whole human genome.

Organoids also provide a window into how cells interact with each other and their environment. They can be used to create cellular models of human disease, which can be studied in the laboratory to better understand the causes of disease and identify possible treatments. The effects of different drugs and be tested.

Scientists have even used gene editing techniques (CRISPR-Cas9) on the stem cells to to introduce targeted mutations in genes corresponding to two different kidney diseases. When these modified pluripotent cells grew into human kidney organoids, they exhibited the diseases.

Using such organoids relieves the scientific community from experimenting on human and animal subjects. Also, certain treatments that would be unethical to administer on the latter, can be tested on the organoids.

With organoids, researchers can produce a limitless supply of tissue from each patient. This will also be extremely useful for the study of rare diseases, where the number of patients on which to conduct research and test treatments is limited.

Organoids are also being used to develop personalised and precision medicine.

For example, it was found that repairing the CFTR protein could give relief to a patient suffering from non-cystic fibrosis, an inherited disease caused due to a gene mutation. Using the Intestinal organoids grown from a patients stem cells, the doctors could quantify the patients response to the CFTR modulating therapy.

Organoids can have significant therapeutic applications. For example, pluripotent stem cells derived from a diabetes patient could be transformed into insulin-producing beta-like cells.

Organoids also offer an incredible opportunity to study developmental biology. Using them, for example, we can learn more about how organs are formed in embryonic stages and associated disorders.

Excerpt from:
Growing Human Organs In A Lab: As Scientists Develop Pathbreaking Three-Organ System, Heres All You Need To Know - Swarajya

New Podcast Sponsored by Asymmetrex Increases Awareness to the Need for Stem Cell Dose in Stem Cell Treatments – PR Web

Asymmetrex Sponsors Podcast on "Counting Stem Cells for a New Era of Medicine"

BOSTON (PRWEB) November 06, 2019

In October, Massachusetts stem cell biotechnology company Asymmetrex launched a new podcast to provide information to patients about a poorly disclosed deficiency in stem cell treatments. Throughout stem cell medical practice, stem cell treatments are given without knowing the dose of the treating stem cells. This problem affects all patients receiving stem cell treatments, including patients receiving approved treatments in routine clinical practice, patients volunteering for experimental treatments in FDA-authorized clinical trials, and patients obtaining unapproved treatments in private stem cell clinics.

The costs and dangers of unknown stem cell dose in treatments are significant. Stem cell clinical trials cannot be interpreted without knowing the treatment dose, leading to huge wastes of both federal and private clinical research dollars. In the case of manufactured stem cells, many treatments may contain very few or no stem cells at all. It is impossible for doctors to improve treatments without knowing the stem cell dose. Stem cell donors for approved treatments like blood stem cell transplantation are scarce. Knowing the stem cell dose would allow doctors to know when a treatment sample has enough stem cells to treat more than one patient; or when it does not have enough to treat even a single patient. In the second case, not knowing the stem cell dose can result in the death of children treated for leukemia when unknowingly they receive an umbilical cord blood transplant with too few blood stem cells to save them.

Earlier this year, the FDA recognized the pressing need for stem cell dose in stem cell medicine. The agencys Standards Coordinating Body for Regenerative Medicine (SCB) listed stem cell dose determination as a priority for needed standards for stem cell medicine. Dose is a fundamental principle for the discovery, development, and administration of quality medicines. Asymmetrex Director James L. Sherley, M.D., Ph.D., who is featured in the new podcast, says that, Dose is essential for stem cell medicine as well. The new podcast has the goal of informing the end users of stem cell treatments: the patients, their doctors, their families, and their advocates, including the FDA. When the people most impacted by these treatments understand that knowing the dose of stem cells is just as important as knowing the dose of their other medicines, they will be empowered to demand this essential certification of the integrity of their stem cell treatments.

The first episode of the podcast, Counting Stem Cells For A New Era Of Medicine, aired online on October 17. The third episode of the biweekly, 6-episode series is scheduled for airing November 12. Each episode features an interview of Asymmetrex Director Sherley by podcast producer Jordan Rich. Mr. Rich guides Dr. Sherley through a discussion of questions that reveal the current challenges that Asymmetrex is addressing to achieve full adoption of stem cell dose as a routine practice in stem cell medicine. The series also highlights other significant applications for stem cell counting in drug development and environmental health science. In conjunction with this educational effort, the company is also sponsoring a study on its website to evaluate the current state of public, academic, and industry knowledge of coming changes in stem cell medicine related to the adoption of stem cell dose.

About Asymmetrex

Asymmetrex, LLC is a Massachusetts life sciences company with a focus on developing technologies to advance stem cell medicine. Asymmetrexs founder and director, James L. Sherley, M.D., Ph.D. is an internationally recognized expert on the unique properties of adult tissue stem cells. The companys patent portfolio contains biotechnologies that solve the two main technical problems production and quantification that have stood in the way of successful commercialization of human adult tissue stem cells for regenerative medicine and drug development. In addition, the portfolio includes novel technologies for isolating cancer stem cells and producing induced pluripotent stem cells for disease research purposes. Asymmetrex markets the first technology for determination of the dose and quality of tissue stem cell preparations (the AlphaSTEM Test) for use in stem cell transplantation therapies and pre-clinical drug evaluations.

Share article on social media or email:

See the original post here:
New Podcast Sponsored by Asymmetrex Increases Awareness to the Need for Stem Cell Dose in Stem Cell Treatments - PR Web